Summit Therapeutics reports Q3 loss on higher R&D spending

Overview

• US oncology drugmaker posted Q3 net loss as R&D expenses rose on expanded clinical trials

• Company received $2 bln equity investment from AstraZeneca after quarter-end to fund ivonescimab development

• Company ended Q3 with $629.8 mln in cash and investments

Outlook

• FDA decision on ivonescimab BLA expected by Nov 14, 2026

• Company expects primary analysis for HARMONi-3 squamous NSCLC cohort in Q4 2026

• Company expects PFS analysis for HARMONi-3 non-squamous NSCLC cohort in H1 2027

Result Drivers

• CLINICAL TRIAL EXPANSION - Co said higher R&D expenses were mainly due to expanded clinical studies and development costs for ivonescimab

• INFRASTRUCTURE AND HEADCOUNT - Co said G&A expense increase was driven by expanded infrastructure and headcount to support ivonescimab development

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Summit Therapeutics Inc. is $32.00, about 102.5% above its November 3 closing price of $15.80

Reuters Recommended Reads

• Nov 4 - Aprea Therapeutics Q3 net loss widens on higher R&D spending

• Nov 4 - Solid Biosciences Q3 net loss widens on higher R&D costs

• Nov 4 - Cytokinetics Q3 net loss narrows as net product revenue rises

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)